Core Insights - The SAPA-China2025 Pharmaceutical Industry Conference was held in Suzhou High-tech Zone, focusing on innovative drug development, cell/gene therapy, AI in medicine, and high-end formulations, among other areas [1] - The conference attracted over 10,000 participants, including leaders from major multinational pharmaceutical and biotech companies, and aimed to enhance collaboration and investment in the pharmaceutical sector [1] - The conference also established a new think tank for the development of the biopharmaceutical industry in the Suzhou High-tech Zone, which will provide expert support for attracting international technologies and resources [1] Industry Development - Suzhou has implemented a series of policy measures to support the construction of a national advanced manufacturing cluster for biopharmaceuticals and high-end medical devices, gathering over 4,200 related enterprises, including nearly 600 large-scale companies [2] - The biopharmaceutical and high-end medical device cluster in Suzhou was included in the list of 45 national advanced manufacturing clusters, with an industrial output value of nearly 240 billion yuan last year [2] - The Suzhou High-tech Zone is one of the most dynamic areas for technological innovation, housing over 1,400 medical device and biopharmaceutical companies, with an output value exceeding 60 billion yuan and an annual growth rate of over 30% [2]